All treatments
Treatment
Abelacimab 150 mg/ml solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase II and Phase III (Integrated)
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
This study looks at a new drug, abelacimab, compared to a standard drug, apixaban, for treating blood clots in veins (VTE) in people with cancer. The main goal is to see which drug is better at preventing new clots and causing less bleeding over six months.
For: venous thromboembolism (VTE)Latvia · Ireland · Italy - Ongoing, recruitingPhase II and Phase III (Integrated)
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
This study looks at a new medicine called abelacimab for people with cancer-related blood clots. It compares abelacimab to a common blood thinner, dalteparin, to see which is better at preventing new clots and causing fewer bleeds.
For: venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancerNorway · France · Hungary